JP2014532060A5 - - Google Patents

Download PDF

Info

Publication number
JP2014532060A5
JP2014532060A5 JP2014534626A JP2014534626A JP2014532060A5 JP 2014532060 A5 JP2014532060 A5 JP 2014532060A5 JP 2014534626 A JP2014534626 A JP 2014534626A JP 2014534626 A JP2014534626 A JP 2014534626A JP 2014532060 A5 JP2014532060 A5 JP 2014532060A5
Authority
JP
Japan
Prior art keywords
alkyl
substituted
heterocycloalkyl
halo
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014534626A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014532060A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/058298 external-priority patent/WO2013052417A1/en
Publication of JP2014532060A publication Critical patent/JP2014532060A/ja
Publication of JP2014532060A5 publication Critical patent/JP2014532060A5/ja
Pending legal-status Critical Current

Links

JP2014534626A 2011-10-03 2012-10-01 癌を治療するためのピロロピリミジン化合物 Pending JP2014532060A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161542392P 2011-10-03 2011-10-03
US61/542,392 2011-10-03
US201161547183P 2011-10-14 2011-10-14
US61/547,183 2011-10-14
PCT/US2012/058298 WO2013052417A1 (en) 2011-10-03 2012-10-01 Pyrrolopyrimidine compounds for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016255095A Division JP6316925B2 (ja) 2011-10-03 2016-12-28 癌を治療するためのピロロピリミジン化合物

Publications (2)

Publication Number Publication Date
JP2014532060A JP2014532060A (ja) 2014-12-04
JP2014532060A5 true JP2014532060A5 (OSRAM) 2016-03-03

Family

ID=48044101

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014534626A Pending JP2014532060A (ja) 2011-10-03 2012-10-01 癌を治療するためのピロロピリミジン化合物
JP2016255095A Active JP6316925B2 (ja) 2011-10-03 2016-12-28 癌を治療するためのピロロピリミジン化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016255095A Active JP6316925B2 (ja) 2011-10-03 2016-12-28 癌を治療するためのピロロピリミジン化合物

Country Status (13)

Country Link
US (3) US9273056B2 (OSRAM)
EP (1) EP2763988B1 (OSRAM)
JP (2) JP2014532060A (OSRAM)
KR (1) KR102063098B1 (OSRAM)
CN (1) CN103958510B (OSRAM)
AU (1) AU2012318896B2 (OSRAM)
BR (1) BR112014007788A2 (OSRAM)
CA (1) CA2850617A1 (OSRAM)
ES (1) ES2650630T3 (OSRAM)
IL (1) IL231835A0 (OSRAM)
MX (1) MX2014004086A (OSRAM)
RU (1) RU2631655C2 (OSRAM)
WO (1) WO2013052417A1 (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011146313A1 (en) 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
BR112014007788A2 (pt) 2011-10-03 2017-04-18 Univ North Carolina Chapel Hill compostos de pirrolopirimidina para tratamento do câncer
MX2014013632A (es) 2012-05-22 2015-02-05 Univ North Carolina Compuestos de pirimidina para el tratamiento de cancer.
WO2014018535A1 (en) 2012-07-25 2014-01-30 Salk Institute For Biological Studies Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine
US9562047B2 (en) 2012-10-17 2017-02-07 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
WO2014085225A1 (en) 2012-11-27 2014-06-05 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
US9603850B2 (en) 2014-04-11 2017-03-28 The University Of North Carolina At Chapel Hill MerTK-specific pyrazolopyrimidine compounds
CN106188060A (zh) * 2015-04-29 2016-12-07 厦门大学 嘧啶并吡咯类化合物、其制备方法、药用组合物及其应用
US9840503B2 (en) 2015-05-11 2017-12-12 Incyte Corporation Heterocyclic compounds and uses thereof
WO2017027717A1 (en) 2015-08-12 2017-02-16 Incyte Corporation Bicyclic fused pyrimidine compounds as tam inhibitors
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
US20180296561A1 (en) * 2015-10-07 2018-10-18 The University Of North Carolina At Chapel Hill The Methods For Treatment Of Tumors
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
WO2017172596A1 (en) 2016-03-28 2017-10-05 Incyte Corporation Pyrrolotriazine compounds as tam inhibitors
AU2017326006B2 (en) * 2016-09-16 2021-10-28 Vitae Pharmaceuticals, LLC. Inhibitors of the menin-MLL interaction
CN110177553A (zh) * 2016-11-17 2019-08-27 北卡罗来纳大学教堂山分校 烷基吡咯并嘧啶类似物及其制备和使用方法
CA3077308A1 (en) 2017-09-27 2019-04-04 Incyte Corporation Salts of pyrrolotriazine derivatives useful as tam inhibitors
WO2019113190A1 (en) 2017-12-07 2019-06-13 Array Biopharma Inc. Bicyclic fused pyridine compounds as inhibitors of tam kinases
CA3086714A1 (en) * 2017-12-28 2019-07-04 Development Center For Biotechnology Heterocycle compounds as tyro3, axl and mertk (tam) family of receptor tyrosine kinase inhibitors
PL3813800T3 (pl) 2018-06-29 2025-08-18 Incyte Corporation Formulacje inhibitora axl/mer
KR102163494B1 (ko) * 2018-10-26 2020-10-08 한국과학기술연구원 단백질 키나아제 저해제인 헤테로방향족 매크로시클릭 유도체
KR102848297B1 (ko) * 2019-04-02 2025-08-20 메릭스 인코포레이티드 키나아제 억제제의 다형체, 이러한 화합물을 함유하는 약학 조성물, 제조 방법 및 용도
AU2021230385A1 (en) 2020-03-06 2022-09-22 Incyte Corporation Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
CN112043710A (zh) * 2020-09-28 2020-12-08 广州智睿医药科技有限公司 一种治疗或预防与lrrk2激酶或异常lrrk2突变激酶活性相关疾病的药物
CN115073469B (zh) * 2021-03-15 2023-12-22 药雅科技(上海)有限公司 吡咯并嘧啶类化合物作为激酶抑制剂的制备及其应用
WO2025170773A1 (en) * 2024-01-26 2025-08-14 The University Of North Carolina At Chapel Hill Tam-family degraders and uses thereof

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958930A (en) 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
WO1997049706A1 (en) * 1996-06-25 1997-12-31 Novartis Ag SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF
US20080248046A1 (en) 1997-03-17 2008-10-09 Human Genome Sciences, Inc. Death domain containing receptor 5
AR035885A1 (es) * 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
DE60228103D1 (de) 2001-10-02 2008-09-18 Smithkline Beecham Corp Chemische verbindungen
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
US7589086B2 (en) 2003-05-28 2009-09-15 Universita Degli Studi Di Siena Substituted pyrazolo[3,4-D]pyrimidines as anti-tumor agents
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
GB0320728D0 (en) 2003-09-04 2003-10-08 Kilminster Shaun Test
EA010160B1 (ru) 2003-09-18 2008-06-30 Конформа Терапьютикс Корпорейшн Новые гетероциклические соединения - ингибиторы hsp90 и способы их получения
DE602005023587D1 (de) 2004-01-21 2010-10-28 Univ Emory Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen
CA2553724A1 (en) 2004-02-03 2005-08-18 Abbott Laboratories Aminobenzoxazoles as therapeutic agents
PL1713806T3 (pl) * 2004-02-14 2013-09-30 Irm Llc Związki i kompozycje jako inhibitory kinaz białkowych
US7956060B2 (en) 2004-03-30 2011-06-07 Kyowa Hakko Kirin Co., Ltd. Pyrimidine derivative compound
JP4790703B2 (ja) * 2004-04-07 2011-10-12 武田薬品工業株式会社 環式化合物
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006035067A2 (en) 2004-09-30 2006-04-06 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-heterocyclyl pyrimidines
WO2006042102A2 (en) * 2004-10-05 2006-04-20 Neurogen Corporation Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
EP1710246A1 (en) 2005-04-08 2006-10-11 Schering Aktiengesellschaft Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer
WO2007035963A2 (en) * 2005-09-23 2007-03-29 Conforma Therapeutics Corporation Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
US7642266B2 (en) 2005-10-06 2010-01-05 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
EA017812B1 (ru) 2005-12-08 2013-03-29 Медарекс, Инк. Выделенное моноклональное антитело или его антигенсвязывающий участок, которые связываются с протеинтирозинкиназой 7 ( ptk7) человека, и их применение
WO2007075554A2 (en) 2005-12-19 2007-07-05 Osi Pharmaceuticals, Inc. Combination of igfr inhibitor and anti-cancer agent
EP1803723A1 (de) 2006-01-03 2007-07-04 Bayer Schering Pharma Aktiengesellschaft (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximid derivate als selektive inhibitoren der aurora kinase zur behandlung von krebs
WO2007113254A1 (en) 2006-03-30 2007-10-11 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-amido substituted pyrimidines
US7998978B2 (en) 2006-05-01 2011-08-16 Pfizer Inc. Substituted 2-amino-fused heterocyclic compounds
GB0610242D0 (en) 2006-05-23 2006-07-05 Novartis Ag Organic compounds
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
AU2008296479A1 (en) 2007-08-28 2009-03-12 Dana Farber Cancer Institute Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
NZ584454A (en) 2007-10-12 2011-09-30 Ingenium Pharmaceuticals Gmbh N-[6-phenyl-pyrimidin-4-yl]-amides and urea derivatives as inhibitors of protein kinases
WO2010008411A1 (en) * 2007-11-09 2010-01-21 The Salk Institute For Biological Studies Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8399206B2 (en) 2008-07-10 2013-03-19 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US20120230991A1 (en) 2008-07-29 2012-09-13 Douglas Kim Graham Methods and compounds for enhancing anti-cancer therapy
WO2010030781A2 (en) 2008-09-10 2010-03-18 Numed International, Inc. Aromatic carboxylic acid derivatives for treatment and prophylaxis of gastrointestinal diseases including colon cancer
TW201016676A (en) 2008-10-03 2010-05-01 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
GB0819105D0 (en) * 2008-10-17 2008-11-26 Chroma Therapeutics Ltd Pyrrolo-pyrimidine compounds
WO2010068863A2 (en) 2008-12-12 2010-06-17 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
WO2010085597A1 (en) 2009-01-23 2010-07-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
TW201102391A (en) * 2009-03-31 2011-01-16 Biogen Idec Inc Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
AR076550A1 (es) 2009-05-06 2011-06-22 Portola Pharm Inc Inhibidores de la janus tirosina kinasa (jak)
JP5883384B2 (ja) 2009-08-13 2016-03-15 ザ ジョンズ ホプキンス ユニバーシティー 免疫機能を調節する方法
EA201200471A1 (ru) 2009-09-10 2012-10-30 Новартис Аг Простые эфирные производные бициклических гетероарилов
WO2011065800A2 (ko) 2009-11-30 2011-06-03 주식회사 오스코텍 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물
WO2011103441A1 (en) 2010-02-18 2011-08-25 Schering Corporation Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
WO2011133920A1 (en) 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
WO2011146313A1 (en) * 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
JP2014005206A (ja) 2010-10-22 2014-01-16 Astellas Pharma Inc アリールアミノヘテロ環カルボキサミド化合物
AU2011330730B2 (en) 2010-11-18 2016-02-18 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
US8362023B2 (en) 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
US9376438B2 (en) 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
CA2846431A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
CN103814030A (zh) * 2011-09-22 2014-05-21 辉瑞大药厂 吡咯并嘧啶及嘌呤衍生物
BR112014007788A2 (pt) 2011-10-03 2017-04-18 Univ North Carolina Chapel Hill compostos de pirrolopirimidina para tratamento do câncer
WO2013124324A1 (en) 2012-02-21 2013-08-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Tam receptors as virus entry cofactors
CA2869954C (en) 2012-04-20 2023-01-03 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof in medical conditions related to modulation of bruton's tyrosine kinase activity
MX2014013632A (es) 2012-05-22 2015-02-05 Univ North Carolina Compuestos de pirimidina para el tratamiento de cancer.
US9562047B2 (en) 2012-10-17 2017-02-07 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
WO2014085225A1 (en) 2012-11-27 2014-06-05 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
US20170202847A1 (en) 2014-04-04 2017-07-20 The University Of North Carolina At Chapel Hill Methods for the treatment of tumors
US9603850B2 (en) 2014-04-11 2017-03-28 The University Of North Carolina At Chapel Hill MerTK-specific pyrazolopyrimidine compounds

Similar Documents

Publication Publication Date Title
JP2014532060A5 (OSRAM)
JP2011154353A5 (OSRAM)
JP2013514367A5 (OSRAM)
JP2009507932A5 (OSRAM)
JP2013538683A5 (OSRAM)
MY177250A (en) Novel nicotinamide derivative or salt thereof
JP2013516518A5 (OSRAM)
SMT201300085B (it) Composti di pirrolo
JP2017119663A5 (OSRAM)
JP2015530408A5 (OSRAM)
JP2008525416A5 (OSRAM)
CO6251317A2 (es) Procedimiento para sintetizar sal diclorhidrato de ((1s)-1-(((2s) sal diclorhidrato de ((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2s)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1h-imidazol-5-il)-4-bifenilil)-1h-imidazol-2-il)-1-pirrolidinil
JP2009535358A5 (OSRAM)
JP2013210632A5 (OSRAM)
EP2634174A3 (en) Nitrogen-containing hetercyclic derivate having 2-imino group and pest control agent including the same
JP2016506958A5 (OSRAM)
JP2012140436A5 (ja) 物質
JP2016520647A5 (OSRAM)
JP2014526533A5 (OSRAM)
JP2010531293A5 (OSRAM)
JP2013533253A5 (OSRAM)
JP2013523975A5 (OSRAM)
HRP20210562T1 (hr) Karbohidratni ligandi koji se vežu na igm antitijela koja djeluju protiv glikoproteina povezanog s mijelinom
AR087148A1 (es) Imidazopiridazinas
DE502008001409D1 (de) Bisamid-zinkbasen